Q2: Plus Therapeutics Beats Estimates, Eos Energy Falls Short
- August 14th, 2023
- 458 views
Plus Therapeutics, Inc. (Nasdaq: PSTV), a pharmaceutical company, delivered a second-quarter 2023 loss of $(0.59) per share, surpassing the consensus estimate loss of $(1.91) per share. The company posted quarterly sales of $1.85 million, outperforming analysts' anticipated revenue of $790 thousand.
$PSTV was trading at $2.70 in after-hours, up $0.20 (+8.00%)
Meanwhile, Eos Energy Enterprises, Inc. (Nasdaq: EOSE), a player in the energy sector, reported a Q2 2023 loss of $(1.12) per share, falling short of the consensus estimate loss of $(0.37) per share. Additionally, the company generated quarterly sales of $249.00 thousand, missing analysts' projected revenue of $2.33 million for the period.
In after-hours, $EOSE was trading at $2.37, down $0.01 (-0.42%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
DOT, DoW, DHS Join Forces to Protect Southern Border Airspace
October 16th, 2026FTC Sues Ticket Broker Over Unlawful Tactics Used to Buy Millions of Tickets to Popular Live Events
October 15th, 2026October 15th, 2026FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
October 14th, 2026U.S. Treasury Announces Record Enforcement Actions Against Bank of America
October 14th, 2026




Member Login